KYMERA THERAPEUTICS, INC. Payments to Acquire Investments
KYMERA THERAPEUTICS, INC. (KYMR) reported Payments to Acquire Investments of $390.92 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInvestments · last filed 2026-08-05
- KYMERA THERAPEUTICS, INC. payments to acquire investments for the quarter ending 2026-06-30 was $114.66M, a 96.83% increase year-over-year.
- KYMERA THERAPEUTICS, INC. payments to acquire investments for the quarter ending 2026-03-31 was $276.27M, a 230.24% increase year-over-year.
- KYMERA THERAPEUTICS, INC. payments to acquire investments for the quarter ending 2025-09-30 was $367.56M, a 24.20% increase year-over-year.
- KYMERA THERAPEUTICS, INC. payments to acquire investments for the quarter ending 2025-06-30 was $58.25M, a 44.07% decline year-over-year.
| Period end | Payments to Acquire Investments 3 month | Payments to Acquire Investments 6 month | Payments to Acquire Investments 9 month |
|---|---|---|---|
| 2026-06-30 | $114.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $390.92M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $276.27M 10-Q · filed 2026-04-30 | ||
| 2025-09-30 | $367.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $425.81M derived: sum of 2 quarters · filed 2026-08-05 | $509.46M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $58.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $141.91M 10-Q · filed 2026-08-05 | |
| 2025-03-31 | $83.66M 10-Q · filed 2026-04-30 | ||
| 2024-09-30 | $295.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $400.10M derived: sum of 2 quarters · filed 2025-11-04 | $822.80M 10-Q · filed 2025-11-04 |
| 2024-06-30 | $104.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $526.86M 10-Q · filed 2025-08-11 | |
| 2024-03-31 | $422.70M 10-Q · filed 2025-05-09 | ||
| 2023-09-30 | $29.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $81.81M derived: sum of 2 quarters · filed 2024-10-31 | $143.65M 10-Q · filed 2024-10-31 |
| 2023-06-30 | $52.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $114.48M 10-Q · filed 2024-08-07 | |
| 2023-03-31 | $61.84M 10-Q · filed 2024-05-02 | ||
| 2022-09-30 | $153.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $218.62M derived: sum of 2 quarters · filed 2023-11-02 | $298.74M 10-Q · filed 2023-11-02 |
| 2022-06-30 | $64.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $144.83M 10-Q · filed 2023-08-03 | |
| 2022-03-31 | $80.12M 10-Q · filed 2023-05-04 | ||
| 2021-09-30 | $245.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $275.99M derived: sum of 2 quarters · filed 2022-11-03 | $292.01M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $30.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $46.16M 10-Q · filed 2022-08-09 | |
| 2021-03-31 | $16.01M 10-Q · filed 2022-05-03 | ||
| 2020-09-30 | $350.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $424.93M derived: sum of 2 quarters · filed 2021-11-10 | $460.94M 10-Q · filed 2021-11-10 |
| 2020-06-30 | $74.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $110.53M 10-Q · filed 2021-08-06 | |
| 2020-03-31 | $36.01M 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |